News

The Study, which is a Phase IIa trial, will be conducted under the leadership of principal investigator, Andrea Branch, PhD, Professor of Medicine in the Icahn School of

KYNAMRO is approved in the United States for use in patients with homozygous familial hypercholesterolemia (HoFH) to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC)

This is the first company sponsored clinical trial evaluating the safety, tolerability, and efficacy of TG-1101 in autoimmune diseases. The Company is also supporting an investigator-sponsored study at

Papulopustular rosacea is a chronic skin disorder characterized by facial redness and inflammatory lesions. It affects more than 16 million people in the U.S. alone. The most common

The US based biotechnology company plans to make hemophilia business a publicly traded independent company, so that each of the company will focus on their respective areas of

As per the agreement, Ionis will receive up to $95m and will earn royalties on global sales of Kynamro starting in 2017. Ionis will also receive a 10%

The complainant is a 62-year-old American woman named Gloria Ristesund. She said that she had used J&J’s talc-based powder products, which include the Baby Powder and Shower to

Spero Oncology is a UK-based CRO specializing in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the

The dose of PRTX-100 for subjects in the next treatment group (6.0 micrograms/kg) will be twice that of the initial starting dosage (3.0 micrograms/kg). PRTX-100, Protalex’s lead drug